Catalent has acquired the gene therapy contract development and manufacturing organisation Paragon in an all-cash deal worth $ $200m . (AAV) vectors, which are considered to be the most preferred vector to inject DNA to cells. The agreement, initially announced in Last month , has now been finalised following the expiration of customary closure waiting periods. Paragon Bioservices , which specialises in the development of adeno-associated virus vectors, is expected to strengthen Paragon 's position in the market for gene therapies while also expanding its research and manufacturing capabilities.
Catalent has acquired the gene therapy contract development and manufacturing organisation Paragon in an all-cash deal worth $ $200m . The agreement, initially announced in Last month , has now been finalised following the expiration of customary closure waiting periods. Paragon Bioservices , which specialises in the development of adeno-associated virus vectors, is expected to strengthen Paragon 's position in the market for gene therapies while also expanding its research and manufacturing capabilities.